<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-74989</identifier>
<setSpec>1130-1406</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Current indications of voriconazole in onco-hematological patients</dc:title>
<dc:description xml:lang="en">Invasive fungal infections (IFI) are the main cause of infectious death in cancerpatients, especially in hematological malignancies and hematopoietictransplant recipients. Current epidemiology is characterized by apredominance of IFI caused by molds, mainly aspergillosis, along with aemergence of hard-to-treat fungi such are Zygomicetes, Fusarium andScedosporium. Voriconazole is a broad spectrum antifungal agent with oraland intravenous formulations, approved by the EMEA for the treatment ofinvasive aspergillosis, candidemia in non-neutropenic patients, IFI caused byfluconazole-resistant species of Candida as well as Scedosporium. andFusarium infections. However, its use in clinical practice is broader, asempirical antifungal treatment and as secondary prophylaxis. It should be keptin mind the possibility of breakthrough IFI, particularly zygomycosis, in patientstreated with voriconazole for long periods(AU)</dc:description>
<dc:creator>Sanz, Miguel A</dc:creator>
<dc:creator>Jarque, Isidro</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las infecciones fúngicas invasoras (IFI) son la principal causa de mortalidadinfecciosa en pacientes con cáncer, especialmente con neoplasiashematológicas y receptores de trasplante de progenitores hematopoyéticos.La epidemiología actual se caracteriza por el predominio de las IFI por mohos,fundamentalmente aspergilosis, junto a la emergencia de hongos de difíciltratamiento como Zigomicetos, Fusarium y Scedosporium. Voriconazol es unantifúngico de amplio espectro con formulación oral e intravenosa, aprobadopor la EMEA para el tratamiento de aspergilosis invasora, candidemia enpacientes no neutropénicos, IFI por especies de Candida resistentes afluconazol e infecciones por Scedosporium y Fusarium. Sin embargo, su usoen la práctica es más amplio, como tratamiento antifúngico empírico y en laprofilaxis secundaria. Debe tenerse en cuenta la posibilidad de IFI de brecha,sobre todo zigomicosis, en pacientes tratados con voriconazol duranteperíodos prolongados(AU)</dc:description>
<dc:source>Rev Iberoam Micol;24(3): 213-216, 2007.</dc:source>
<dc:identifier>ibc-74989</dc:identifier>
<dc:title xml:lang="es">Indicaciones actuales de voriconazol en pacientes onco-hematológicos</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d9691^s22012</dc:subject>
<dc:subject>^d32203</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d943^s22073</dc:subject>
<dc:subject>^d32857^s22074</dc:subject>
<dc:subject>^d1414^s22073</dc:subject>
<dc:subject>^d32936^s22012</dc:subject>
<dc:subject>^d33754^s22057</dc:subject>
<dc:subject>^d5807^s22021</dc:subject>
<dc:subject>^d11622^s22057</dc:subject>
<dc:subject>^d30095^s22057</dc:subject>
<dc:subject>^d35306^s22021</dc:subject>
<dc:subject>^d9373^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200700</dc:date>
</metadata>
</record>
</ibecs-document>
